Objective-A comprehensive meta-analysis of clinical trial data was performed to assess the possible association of fluoxetine and suicidality (suicidal acts and ideation).
Introduction
Because depression is an important risk factor for suicide"
there is a need IO study the effects of antidepressants on suicidality (suicidal acts and suicidal ideation) in patients with major depressive illnesses. Though it is generally expected that any treatment that improves the depression is also likely to reduce suicidality, one study did not support this view.' It has not been suggested until fairly recently that, paradoxically, worsening of suicidality might in a small subset of patients be associated with the use of antidepressants.'-" Five reportP" (one subsequently retracted") have hypothesised that the use of fluoxetine (a serotonin uptake inhibitor) might lead to the emergence or worsening of suicidal ideation in a very small proportion of patients taking this drug. Patients receiving different classes of antidepressants, including fluoxetine, have shown no differences in rates of suicidality,'* while greater improvement with respect to suicidality has occurred with serotonin uptake inhibitors than with comparative drugs in depressive illnesses.'3-16 Recently Rouillon et al reported that maprotiline (a noradrenaline uptake inhibitor) was associated with a greater incidence of suicidal acts than placebo during long term treatment of depression." To examine any possible relation of fluoxetine to the emergence of suicidality, we carried out a comprehensive meta-analysis of all relevant clinical trial data.
Methods TYPES AND SOURCES OF DATA
The meta-analysis was carried out on the United States investigational new drug depression clinical trial database for fluoxetine; this consists of all double blind, randomised trials of fluoxetine in depression controlled against placebo or tricyclic antidepressants. Trials that had been completed and analysed up to the end of December 1989 were included. The exclusions were: depression trials that had not used a comparative drug, trials that had used a comparator other than placebo or a tricyclic antidepressant, non-blind extensions of controlled trials, non-blind compassionate trials, trials for other potential indications, and pharmacokinetic trials.
For these analyses the clinical trials were organised into five analysis groups: (1) placebo controlled trials (five trials); (2) trials controlled with tricyclic antidepressants (10 trials); (3) trials controlled with placebos and tricyclic antidepressants (two trials); (4) analysis group 1 and the Auoxetine and placebo arms of analysis group 3; and (5) analysis group 2 and the fluoxetine and tricyclic antidepressant arms of analysis group 3. The specific protocols included in each analysis group and the characteristics of the patients studied are surnmarised in the Appendix.
Potential cases of suicidal acts were first identified electronically by searching two sources: (a) clinical report form data from the trials (for adverse events, reasons for trial discontinuation, Hamilton depression rating scale item 3 scores,'* and free text comments) and (b) data from the drug experience network for adverse events and outcomes. The drug experience network database contains reports of all serious adverse events (as defined by United States Food and Drug Administration criteria) that have occurred in clinical trials, as well as all adverse events voluntarily reported as part of the manufacturer's (Eli Lilly and Company) post-marketing surveillance." Those clinical comments that had not been transferred to computer were examined by the research staff, and all cases in which it was clear that there had been no suicidal act were eliminated. All remaining cases were then reviewed independently by two Eli Lilly and Company psychiatrists, who were blind to the drug that had been used, to determine whether or not a suicidal act had occurred.
DEFINITIONS
A suicidal act was defined as any behaviour undertaken purposefully from which the outcome was likely to be self harm, and where no explicit data suggested that suicide had not been intended.' Actions that might be described as suicidal gestures were not excluded. A suicidal act had to have occurred before or during the day following the last day of double blind treatment, in compliance with the trial protocol. This time limit was adopted for three reasons: post-discontinuation data had not been collected as part of the trials; the end of participation in the trial or withdrawal of the study treatment, or both, might have influenced an event occurring after discontinuation; and other drugs might have been started after the end of the study treatment.
Suicidal ideation was identified by the scores on item 3 of the Hamilton depression rating scale. The scale defines these as: O=absence of such ideation; 'l=doubtful or trivial ideation; 2=mild ideation; 3= active suicidal ideation and suggestive behaviours; and 4=severe ideation, usually involving a suicidal act.
Emergence of substantial suicidal ideation was defined as a ehange in score on item 3 of the I-Iamilton depression rating scale from 0 or 1 at baseline to 3 or 4 at any time during the double blind treatment. Emergence of substantial suicidal ideation was evaluated only for those patients whose score was 0 or 1 at baseline.
Worsening of suicidal ideation was defined as any increase in item 3 score from baseline at any time during double blind treatment. Worsening was evaluated only for those patients who could worsen during double blind treatment-that is, those whose score was less than 4 at baseline.
Improvement of suicidal ideation was deiined as any decrease in item 3 score from baseline to the last evaluation while the patient was in double blind treatment. Improvement was evaluated only for those patients who could improve during double blind treatment-that is, those whose score was greater than 0 at baseline.
DESIGN
Data were analysed from 17 single centre and multicentre randomised, double blind trials including 3065 patients (1765 receiving fluoxetine, 73 1 receiving tricyclic antidepressants (amitriptyline, desipramine, doxepin, imipramine, nortriptyline), and 569 receiving placebo). Five trials compared fluoxetine with placebo, 10 compared fluoxetine with a tricyclic antidepressant, and two compared fluoxetine with a tricyclic antidepressant and a placebo.
Fluoxetine doses ranged from 20 mg to 80 mg a day (except in one trial where the range was 5 mg to 40 mg a day); in 15 trials the fluoxetine doses were individually adjusted, and in two the patients were randomly assigned to one of several fixed doses. Doses of tricyclic antidepressants were adjusted individually within current manufacturers' guidelines.
In 16 trials the patients met criteria for nonpsychotic major depressive disorder (three trials used Research Diagnostic Criteria,"' nine trials used the Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM-III) criteria for symptoms of one month's duration, and four trials required DSM-III criteria:'). Most patients had a score 220 on the 21 item Hamilton depression rating scale (one trial used a score 2 18 and one trial included a stratum of patients with scores between 14 and 19), and most did not improve their score by 20% or more during the lead in period (approximately one week of single blind placebo treatment). In one trial the patients were diagnosed by DSM-III criteria as having bipolar disorder and being depressed; they had a baseline score 320 on the 2 1 item Hamilton depression rating scale and failed to show a 20% or greater improvement in this score during placebo lead in. Written informed consent was given appropriately in all cases.
Exclusion criteria included a history of substance misuse within one year; psychotic or organic mental disorder; serious suicidal risk as clinically assessed by the investigator (suicidal ideation was not a criterion; two inpatient trials did not have an explicit exclusion criterion based on serious suicidal risk); and unstable medical conditions or any medical condition precluding use of one of the drugs used in these studies.
Trials lasted five or six weeks with evaluations about once a week, except in one inpatient trial where there were two evaluations a week for the first two weeks of double blind treatment and one outpatient trial where there were two evaluations during the first week and three during the second week of double blind treatment. ANALYTICAL 
AND STATISTICAL METHODS
Descriptive statistics, including the incidence of suicidal acts and the emergence of substantial suicidal ideation (the primary measures) and worsening of suicidal ideation and improvement of suicidal ideation, were computed for all individual trials, for analysis groups 4 and 5, and for all trials combined. Inferential statistical analyses were performed for analysis group 4 (fluoxetine 3 placebo), analysis group 5 (fluoxetine a tricyclic antidepressants), and all trials combined. All 3065 randomised patients were included in the analysis of suicidal acts. A total of 1999 patients with a baseline score on item 3 of the Hamilton depression rating scale of 0 or 1 and at least one post-baseline score were included in the analysis of emergence of substantial suicidal ideation. The incidence of worsening of suicidal ideation was based on 2995 patients with a baseline score <4 and at least one post-baseline score. The incidence of improvement of suicidal ideation was based on 2053 patients with a baseline score >Q and at least one post-baseline score.
The incidence difference and corresponding 95% confidence interval was used to compare the incidence of the four outcome variables (suicidal acts, emergence of substantial suicidal ideation, worsening of suicidal ideation, improvement of suicidal ideation) between treatments for individual clinical trials. The incidence difference" was defined as the incidence in patients treated with fluoxetine minus the incidence in patients treated with the comparator. An incidence difference greater than 0 implies a numerically higher incidence with fluoxetine than with the comparator; an incidence difference less than 0 implies a numerically higher incidence with the comparator than with fluoxetine; and an incidence difference equal to 0 implies equal incidence.
Owing to potential heterogeneity of trials the adjusted incidence difference, which stratifies by trial, was used to compare the incidence of the four outcome variables between treatments in analysis groups 4 and 5. The individual incidence differences were combined across the clinical trials to form the adjusted incidence difference (also referred to as the adjusted risk difference) by using the binomial, unconditional Mantel-Haenszel estimate ( Equation 12)." This estimate is an average of the incidence differences of the individual trials weighted by sample size. The variance of the Mantel-Haenszel risk difference (Equation 14)" was used to form the 95% confidence intervals (Equation 19)" for the adjusted incidence differences and the associated p values (Equation 6.37)." When interpreting the adjusted incidence difference we considered the consistency (homogeneity) of the treatment comparisons across trials. To test for lack of homogeneity of treatment comparisons across trials we used the Breslow-Day test.LCZ; Although the BreslowDay test is designed to test for homogeneity of odds ratios across trials, it was used here to test for a lack of homogeneity of treatment comparisons across trials in general. Results of the Breslow-Day test were not significant in any analysis; however, it is still useful to consider treatment comparisons by individual trial. Figures 1-4 (given below) show the incidence differences and 95% confidence intervals for individual trials as well as the adjusted incidence differences and the 95% confidence intervals for analysis groups 4 and 5 for the four outcome variables and allow visual inspection of the treatment comparisons.
In addition to heterogeneity of trials, it was important to consider potential differences in baseline distributions of scores on item 3 of the Hamilton depression rating scale across treatments within trials when comparing worsening and improvement of suicidal ideation. Therefore we performed a test of potential differences in these distributions for treatments in analysis groups 4 and 5. Estimators and test statistics used for these comparisons would have been appropriately adjusted for such differences, but none were found.
The Mantel-Haenszel adjusted incidence difference and its associated p value for analysis groups 4 and 5 constitute the primary inferential analytical method for the four outcome variables. This method adjusts for potential heterogeneity across trials and constitutes the basis for all conclusions discussed. In addition, Pearson's x' tests were used for pairwise comparisons of treatment, combining the data across all 17 trials. This analysis is provided because clinical criteria and trial methods were relatively similar across the 17 trials; it constitutes a secondary inferential analysis for the four outcome variables.
Baseline suicidality was measured by the percentage of patients with passive or active suicidal thinking (score on item 3 of the Hamilton depression rating scale 22) in all patients. Baseline suicidality was measured for all randomised patients with baseline data (2999 of 3065) who had at least one post-baseline measurement.
For all analyses except for the Breslow-Day test statistical significance was defined as p<O.O5. For the Breslow-Day test ~(0.1 was considered significant .
The FREQ procedure in SAS 5.18" was used for the Breslow-Day test and Pearson's ;c' test. The incidence difference for individual trials and the adjusted incidence differences for groups of trials were calculated in an SAS data step.
Results

PATIENTS
CHARACTERISTICS AT BASELINE Table I lists the baseline characteristics of the patients included in these analyses for analysis groups 4 and 5 as well as the total combined population organised by type of treatment. Table II 
pool of patients organised by treatment. It can be consulted when examining the results of the inferential analyses described below.
SUICIDAL ACTS
During the single blind placebo lead in period of these trials, three suicidal acts (one fatal) were identified. One of these patients was continued in the trial, randomised to Auoxetine, and completed double blind treatment without any further suicidal act. Figure I presents the incidence differences for the individual trials and the adjusted incidence differences with 95% confidence intervals and p values for pooled analysis groups 4 and 5. The adjusted incidence difference for fluoxetine compared with placebo was 0.2 (-0.3 to 0.7, p=O.494); for fluoxetine compared with tricyclic antidepressants it was O-3 (-0.4 to 1.1, p=O.419); neither difference approached significance.
The pooled incidence of suicidal acts was 0.3% for
SUICIDAL IDEATION AT BASELINE
Serious suicidal risk, as clinically assessed by the investigator, was an exclusion criterion (except in two trials), but suicidal ideation was not. Analysis of scores for item 3 on the Hamilton depression rating scale, available for 2999 patients, indicated that 1000 (33%) had suicidal ideation at baseline to the extent that the score was > 2. EMERGENCE The pooled incidence of emergence of substantial suicidal ideation was 1.2% for fluoxetine, 2.6% for placebo, and 36% for tricyclic antidepressants. Pearson's x' test showed a lower incidence with fluoxetine than with placebo (p=O-042) or tricyclic antidepressants (p=O.OOl). Figure 3 presents the data for worsening of suicidal ideation. For both comparisons worsening of suicidal ideation was similar with fluoxetine and with placebo or tricyclic antidepressants (fluoxetine versus placebo -2.6 (-6.6 to 1.3)p=O.l96; fluoxetine versus tricyclic antidepressants -0.5 (-4.2 to 3.2) p=O.793).
WORSENING OF SUICIDAL IDEATION
The pooled incidence of worsening of suicidal ideation was 15.3% for fluoxetine, 17.9% for placebo, and 16.3% for tricyclic antidepressants. Pearson's %' test showed no significant difference for either fluoxetine versus placebo (p=O.l41) or fluoxerine versus tricyclic antidepressants (p=O.542). Figure 4 presents the data for improvement of suicidal ideation. There was significantly more improvement with fluoxetine than with placebo (18.8 (12.7 to 24.9), p<O.OOl). Improvement was similar 8 (-2.4  to 8.1), p=O.294) .
IMPROVEMENT OF SUICIDAL IDEATION
The pooled incidence of improvement of suicidal ideation was 72.2% for fluoxetine, 54.8% for placebo, and 69.8% for tricyclic antidepressants. Pearson's t test showed significantly more improvement with fluoxetine than with placebo (p<O.OOl); fluoxetine and tricyclicantidepressants were not significantly different (p=O.296).
Discussion
The occurrence of three suicidal acts during the brief placebo lead in period in a population screened to exclude serious suicidal risk emphasises the inherent danger of suicidality in major depressive disorder and its potential for emerging rapidly. The data analysed here, which were systematically collected in a blinded manner from a large total number of patients, do not show either increased risk of suicidal acts or the emergence of substantial suicidal ideation among patients treated with fluoxetine, relative to the risk with a tricyclic antidepressant or placebo. Suicidal acts were infrequent during double blind, controlled trials of fluoxetine lasting up to six weeks (fluoxetine 0.3%, tricyclic antidepressants 0.4%, placebo 0.2%), and the pairwise comparisons by adjusted incidence differences within the pooled analysis groups did not show significant differences between Auoxetine and either placebo or tricyclic antidepressants. It must be kept in mind that if the 95% confidence interval around the adjusted incidence difference for a comparison of interest contains clinically important values (as defined by the reader) then these data may lack sufficient power due to insufficient sample size. However, for fluoxetine versus placebo this interval was -0.3% to 0.7%, and for fluoxetine versus tricyclic antidepressants it was -0.4% to 1.1%.
Substantial suicidal ideation emerged marginally significantly less often with fluoxetine than with placebo (p=O.O94, Mantel-Haenszel adjusted incidence difference) and numerically less often with fluoxetine than with tricyclic antidepressants (p=O*102). Worsening to any degree at any time during treatment did not differ with lluoxetine compared with placebo or tricyclic antidepressants. A significantly higher percentage of patients treated with fluoxetine experienced improvement than did patients treated with placebo (p<O.OOl); there was no significant difference in improvement between patients treated with fluoxetine and those treated with tricyclic antidepressants.
The results of the Pearson's x2 analyses for the four outcome variables (suicidal acts, emergence of substantial suicidal ideation, worsening of suicidal ideation, and improvement of suicidal ideation) were consistent with the results obtained with the MantelHaenszel adjusted incidence difference analyses. Therefore the x" analyses support the conclusions discussed above drawn from the incidence difference analyses.
The data reported here must be/viewed in the context of epidemiological findings regarding depression and suicidality: 15% of patients with major depression will die by suicide," 20-40% will show suicidal behaviour,Z9 and up to 80% will experience reported that during a 10 year follow up of 954 depressed patients, 68 suicides occurred (0.007 1 suicide deaths per patient year, not adjusted for deaths by other causes)." The number of attempts per completed suicide has been variously estimated between eight and 33, with a reasonable estimate being 10 attempts for each fatal suicide." u Therefore, rates of non-fatal suicidal acts in the cohorts reported by Black it al and Fawcett et al might be estimated to be 0.116 and 0.071 per patient year, respectively.
Muijen et al have reported a significantly greater reduction in suicidal ideation with fluoxetine treatment than with comparators." Sacchetti et al have reported that patients with a history of suicidal acts have a higher rate of response (percentage of patients with a 50% or greater reduction in Hamilton depression rating scale score) to fluoxetine and clomipramine than those without a history of such acts and that suicidal patients also show a higher rate of response to these serotonin uptake inhibitors than to nortriptpline and desipramine. lo Montgomerv and Pinder" and Wakelin" have described studies suggesting that other serotonin uptake inhibitors may also result in significantly better improvement in suicidal ideation. The rate of emergence of suicidal ideation during treatment with fluoxetine presented here is less than half the 3.5% rate suggested in other reportshC The significant (p<O.OOl) superiority of fluoxetine compared with placebo with respect to improvement of suicidal ideation and the marginally significant (p=O.O94, Mantel-Haenszel adjusted incidence difference; p=O.O42, Pearson's x' test) superiority of fluoxetine compared with placebo with respect to emergence of substantial suicidal ideation suggest a potentially beneficial effect for fluoxetine with regard specifically to suicidality. This is consistent with the findings of Muijen et al for fluoxetine, as well as with those described by Montgomery and Pinder and Wakelin for other serotonin uptake inhibitors.13-"
Though the sample size analysed here was large, the possibility cannot be excluded that some extremely rare phenomenon was not detected. Although item 3 on the Hamilton depression rating scale failed to detect significant differences among the treatment groups with respect to operationally defined emergence of substantial suicidal ideation (baseline score of 0 or 1 increasing to 3 or 4 at any time during treatment), it may not detect important changes in rare, individual patients such as those described by Damluji and Ferguson, Teicher er al, and others.s-'9 lo It is possible that among the 1.2% of tluoxetine treated, 3.6% of tricyclic treated, and 2.6% of placebo treated patients who experienced the emergence of substantial suicidal ideation there might have been smaller subsets with some very unusual change that differed among the treatments. What these data show is in fact a lack of increased risk with fluoxetine in these clinical trials of up to six weeks' duration. The results obtained here may not be generalisable to a population with different clinical characteristics (patients more seriously suicidal at start of treatment) who have been treated for a longer period.
There is no dispute that both suicidal ideation and suicidal acts are inherent risks associated with depression in general. Therefore, when starting or continuing treatment of any kind with depressed patients clinicians must always remain vigilant for the emergence of suicidal ideation or change in its severity so that appropriate action can be taken. 
